COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies
Authors:
- Swapnila ChoudhurySCSwapnila Choudhury
- Nafisa NawaarNNNafisa Nawaar
- Woasifur Rahman ChowdhuryWCWoasifur Rahman Chowdhury
- Puja RoyPRPuja Roy
- Auroni Semonti KhanAKAuroni Semonti Khan
- Sajad AliSASajad Ali
- Randa Mohammed ZakiRZRanda Mohammed Zaki
- Topu RaihanTRTopu Raihan
- Meerambika MishraMMMeerambika Mishra
- Muhammad Fazle RabbeeMuhammad Fazle Rabbee
- Kwang-Hyun BaekKwang-Hyun Baek
Open Access
- 6 September 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6896
Abstract
From a health perspective, the 21st century has witnessed the emergence and global impact of several major viral diseases, most notably coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, which has been associated with a substantial burden of secondary fungal infections. Patients suffering from COVID-19 illnesses frequently developed fungal co-infections, which can worsen clinical outcomes and complicate therapeutic efforts. Hospitalized individuals with viral infections are particularly susceptible to invasive fungal pathogens, including Aspergillus, Candida, and Mucorales species. The co-pathogenesis between respiratory virus and fungi is complex, involving dynamic interactions among the pathogens and the host immune system. Opportunistic fungal infections were found to be more prevalent in COVID-19-infected individuals, who require mechanical ventilation, have diabetes, or exhibit neutropenia. This review aims to provide a comprehensive overview of fungal co-infections associated with COVID-19 disease, with a focus on their pathogenesis, biomarkers, diagnostic approaches, and potential treatment strategies. Overall, the available evidence indicates that viral-induced immune dysregulation, epithelial barrier damage, and clinical risk factors contribute to the development and severity of fungal co-infections in COVID-19 patients. Early recognition using reliable biomarkers and standardized diagnostic approaches, together with timely and pathogen-directed antifungal therapy, are essential for improving clinical outcomes.Keywords
Funding Information
- Prince Sattam bin Abdulaziz University (PSAU/2026/R/1447)
- Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia (KFU264958)
- Rural Development Administration (RS-2025-02223124)
This publication has 193 references indexed in Scilit:
- Convalescent Plasma Restores Viral Clearance After Anti‐Spike Monoclonal Antibody Failure in Immunocompromised COVID‐19 Patients: A Systematic Review and Meta‐Analysis of Individual Patient DataReviews in Medical Virology, 2026
- A systematic review on SARS‐CoV‐2‐associated fungal coinfectionsJournal of Medical Virology, 2021
- Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from ChinaMycopathologia, 2020
- (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill peopleCochrane Database of Systematic Reviews, 2020
- Influenza-associated aspergillosis in critically-ill patients—a retrospective bicentric cohort studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Usefulness of 1,3 Beta-d-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii PneumoniaMycopathologia, 2017
- Danger‐associated molecular patterns (DAMPs) in acute lung injuryThe Journal of Pathology, 2012
- Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective studyIntensive Care Medicine, 2012
- Recent Advances in the Treatment of MucormycosisCurrent Infectious Disease Reports, 2010
- A multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samplesMedical Microbiology and Immunology, 2007